GigaGen
  • Our Company
    • Team
    • News
  • Our Science
    • Our Approach
    • Publications, Scientific Posters & Presentations
  • Pipeline
    • Overview
    • Recombinant Monoclonals
    • Recombinant Polyclonals
  • Careers
  • Contact
  • Menu Menu

Targeted Oncology: Novel CTLA-4 Agents Build on Immunotherapy Foundation, Aim to Improve Efficacy/Safety

News, Uncategorized

GIGA-564 featured in the Next Wave of CTLA-4 Blockade. Read the full article.

03/30/2022
Share this entry
  • Share on Facebook
  • Share on X
  • Share on WhatsApp
  • Share on LinkedIn
  • Share by Mail
©2026 Copyright GigaGen. All Rights Reserved. | Privacy Policy | Terms | Disclaimer | Cookie Policy | Cookie Settings | Accessibility Statement - Enfold Theme by Kriesi
  • Link to X
  • Link to LinkedIn
Scroll to top Scroll to top Scroll to top